Myrto Moutafi

10PUBLICATIONS
63CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Apr 20, 2026
Quantification of Antibody-Drug Conjugate Targets in Head and Neck Squamous Cell Carcinoma.

|Jul 16, 2025
Quantitative Multiplex Immunofluorescence Assay for Trophoblast Cell-Surface Antigen 2 and Human Epidermal Growth Factor Receptor 2 Expression in Breast Cancer: Toward Guiding Patient Selection for Antibody-Drug Conjugate Therapies.

Charles J Robbins, Mengni He, Nay Chan

|Jun 27, 2024
Overcoming Resistance to Temozolomide in Glioblastoma: A Scoping Review of Preclinical and Clinical Data.

Dimitra Smerdi, Myrto Moutafi, Ioannis Kotsantis

|Jun 10, 2024
High-throughput transcriptome profiling indicates ribosomal RNAs to be associated with resistance to immunotherapy in non-small cell lung cancer (NSCLC).

Myrto K Moutafi, Katherine M Bates, Thazin Nwe Aung

|Aug 16, 2023
Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases.

David A Schoenfeld, Myrto Moutafi, Sandra Martinez

|Aug 14, 2023
Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer.

Myrto Moutafi, Georgia-Angeliki Koliou, George Papaxoinis

Pageof 2

Frequent Collaborators

9 joint publications

David L Rimm

4 joint publications

Niki Gavrielatou

3 joint publications

Thazin Nwe Aung

2 joint publications

Ioannis Vathiotis